Lantheus (LNTH) Proxy filing summary

Executive summary

• Curium and Lantheus announced a merger, aiming to combine strengths in diagnostics and therapeutics, with completion expected in the first half of 2027 pending shareholder and regulatory approvals.

• The merger is positioned as transformational, expanding offerings in oncology, neurology, and echocardiography, and leveraging PYLARIFY's infrastructure for global launches.

• Both companies will operate independently until the merger closes, with a focus on minimizing disruption and maintaining strategic execution.

• Forward-looking statements highlight anticipated benefits, including enhanced patient access and global scaling of precision medicine.

Voting matters and shareholder proposals

• Shareholders will be asked to approve the merger at a special meeting, with proxy materials to be distributed in advance.

• The merger is subject to shareholder approval and satisfaction of regulatory conditions as outlined in the merger agreement.

Board of directors and corporate governance

• Directors, executive officers, and employees of both companies may participate in the proxy solicitation process.

• Information on directors and executive officers is available in recent SEC filings, with updates to be included in the definitive proxy statement.